MedPath
HSA Approval

PALBOCICLIB SANDOZ CAPSULE 100MG

SIN17006P

PALBOCICLIB SANDOZ CAPSULE 100MG

PALBOCICLIB SANDOZ CAPSULE 100MG

May 9, 2024

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

L01EF01

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Aizant Drug Research Solutions Pvt Ltd.

Active Ingredients

Palbociclib

100.00 mg

Palbociclib

Documents

Package Inserts

PALBOCICLIB SANDOZ Capsule PI.pdf

Approved: May 9, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

PALBOCICLIB SANDOZ CAPSULE 100MG - HSA Approval | MedPath